Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.11.2018 | Case report

Ledipasvir/sofosbuvir/ribavirin

Development of drug resistance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Tsertsvadze T, et al. Emergence of NS5A RASS among HCV RF1-2K/1B patients treated within georgian hepatitis c elimination program: A case report. Hepatology 68 (Suppl. 1): 599A (plus poster) abstr. 1029, Oct 2018. Available from: URL: http://doi.org/10.1002/hep.30257 [abstract] - Georgia Tsertsvadze T, et al. Emergence of NS5A RASS among HCV RF1-2K/1B patients treated within georgian hepatitis c elimination program: A case report. Hepatology 68 (Suppl. 1): 599A (plus poster) abstr. 1029, Oct 2018. Available from: URL: http://​doi.​org/​10.​1002/​hep.​30257 [abstract] - Georgia
Metadaten
Titel
Ledipasvir/sofosbuvir/ribavirin
Development of drug resistance: case report
Publikationsdatum
01.11.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-54472-y

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Antineoplastics

Case report

Cabozantinib

Case report

Immune globulin

Case report

Atorvastatin